Diva Laboratories, Ltd. (4153) AI Stock Analysis

Diva Laboratories, Ltd.

(TPEx:4153)

Select Model

Rating:69Neutral

Price Target:TWD 33.00▲(6.97% Upside)

Action:initiatedcoverage

Date:11/09/26

Diva Laboratories scores well on financial strength and valuation, but weak price momentum holds the overall rating back. The balance sheet is the standout: essentially zero debt against NT$997 million of equity, giving the company substantial flexibility and little financial risk, while margins and earnings have improved steadily over four years, with TTM net income of NT$115 million a period record. Valuation adds support, with a modest 15.6x P/E and a 6.6% dividend yield. Offsetting this, the shares trade below all key moving averages with a negative MACD and a subdued RSI of 38.4, reflecting persistent selling pressure. Investors should also monitor revenue volatility — sales have only just recovered to 2022 levels — and inconsistent cash generation, as operating cash flow covers only about two-thirds of reported profit and is the key factor needed to validate both the earnings recovery and the dividend.

Positive Factors

Conservative Balance SheetNear-zero leverage materially reduces solvency and refinancing exposure while preserving capacity to fund research support and other growth initiatives internally. The equity-funded structure also gives management flexibility through weaker demand cycles.

Negative Factors

Volatile Operating Cash FlowLarge year-to-year swings in operating cash flow reduce confidence in the consistency of cash generation, even with strong TTM free cash flow conversion. TTM operating cash flow is also modest relative to earnings, which may constrain dependable funding for expansion.

Diva Laboratories, Ltd. (4153) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 1.79B
Dividend Yield: 6.48%
Average Volume (3M): 34.75K
Price to Earnings (P/E): 15.9
Beta (1Y): 0.13
Revenue Growth: 9.73%
EPS Growth: 36.89%
Country: TW
Employees: 154
Sector: General
Sector Strength: 55
Industry: Medical - Diagnostics & Research

Diva Laboratories, Ltd. Business Overview & Revenue Model

Company Description

DIVA Laboratories, Ltd. specializes in the global provision of advanced display technologies. Its comprehensive product lineup caters to critical environments, including specialized endo/surgical displays designed to render both static and dynamic im...

Diva Laboratories, Ltd. Financial Statement Overview

Summary

A fortress-like balance sheet (86) anchors the profile: the company is effectively debt-free with NT$1.0 million of debt against NT$997 million of equity, funding 73% of assets and leaving virtually no refinancing or interest-rate risk, while ROE has improved to 11.7%. The income statement (73) shows a genuine profitability recovery — TTM revenue of NT$946 million is up 5.7% year-over-year after three soft years, gross margin has expanded to roughly 30% from 25.5% in 2021, and net margin has reached 12.2% versus 3.1% in 2021. Cash flow (56) is the clear weak spot: operating cash flow has swung widely (negative NT$11 million in 2021, NT$253 million in 2023, NT$21 million in 2025, NT$75 million TTM) and now covers only about two-thirds of reported net income, though light capex means most of it converts to free cash flow. Top-line volatility and inconsistent cash conversion cap the score.

Income Statement

73Positive

Balance Sheet

86Very Positive

Cash Flow

56Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	895.46M	868.84M	862.32M	893.84M	949.20M	712.23M
Gross Profit	258.33M	264.68M	260.18M	250.77M	266.13M	181.60M
EBITDA	112.13M	112.42M	127.10M	101.22M	132.28M	42.29M
Net Income	95.99M	90.54M	93.66M	73.62M	49.66M	21.86M
Balance Sheet
Total Assets	1.47B	1.35B	1.31B	1.24B	1.25B	1.18B
Cash, Cash Equivalents and Short-Term Investments	549.14M	494.10M	589.14M	541.29M	346.37M	300.22M
Total Debt	1.61M	2.90M	4.97M	7.50M	283.00K	411.00K
Total Liabilities	498.70M	324.52M	249.94M	210.93M	235.62M	195.27M
Stockholders Equity	967.23M	1.03B	1.06B	1.03B	1.02B	986.42M
Cash Flow
Free Cash Flow	22.63M	19.77M	121.01M	245.43M	61.77M	-24.24M
Operating Cash Flow	26.05M	20.77M	123.14M	252.91M	73.19M	-11.39M
Investing Cash Flow	-91.00K	5.17M	3.86M	-3.20M	-5.05M	2.62M
Financing Cash Flow	-120.06M	-120.13M	-76.07M	-59.13M	-22.04M	-15.49M

Diva Laboratories, Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4153 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:5315	75Outperform	TWD 1.85B	10.66	―	9.04%	2.53%	3.36%
TW:4153	69Neutral	TWD 1.74B	15.93	―	6.48%	9.73%	36.89%
TW:3284	62Neutral	TWD 1.84B	7.08	―	2.92%	8.49%	51.70%
TW:4116	62Neutral	TWD 1.82B	2.38	―	4.91%	3.85%	786.65%
TW:4995	57Neutral	TWD 1.71B	10.22	―	5.00%	14.06%	111.77%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:3285	53Neutral	TWD 1.89B	26.96	―	1.03%	25.00%	430.27%

* General Sector Average

Performance Comparison

TW:4153 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4153	Diva Laboratories, Ltd.	30.85	-1.42	-4.41%
TW:3284	Top High Image Corp.	17.15	-5.65	-24.78%
TW:3285	Microtips Technology Inc.	48.60	21.25	77.68%
TW:4116	BenQ Medical Technology Corp.	40.70	-3.48	-7.87%
TW:4995	Litemax Electronics Inc.	39.85	-1.83	-4.39%
TW:5315	United Radiant Technology Corporation	17.70	-4.63	-20.73%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Diva Laboratories, Ltd. AI Stock Analysis